ChemoCentryx Up Most Since 2019 on Autoimmune Drug Approval – Yahoo Finance
Business News
- ChemoCentryx Up Most Since 2019 on Autoimmune Drug Approval Yahoo Finance
- ChemoCentryx’s stock jumps 80% after receiving FDA approval for vasculitis drug MarketWatch
- ChemoCentryx Shares Are Spiking After an Unexpected FDA Approval Barron’s
- ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis Yahoo Finance
- FDA approves ChemoCentryx’s Tavneos for treatment of vasculitis Seeking Alpha
- View Full Coverage on Google News
Source: Business News